Nicola Jane Lawrence

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

Ian D. Davis, Andrew Martin, Martin R. Stockler et al. · New England Journal of Medicine · 2019 · 1.6K citations

Pharmacy, Oncology, Pharmacotherapy +17

[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

Michael S. Hofman, Louise Emmett, Shahneen Sandhu et al. · The Lancet · 2021 · 1.1K citations

Medicine, Oncology, Pharmacology +12

TheraP: a randomized phase 2 trial of ¹⁷⁷ Lu‐ <scp>PSMA</scp> ‐617 theranostic treatment vs cabazitaxel in progressive metastatic castration‐resistant prostate cancer (Clinical Trial Protocol <scp>ANZUP</scp> 1603)

Michael S. Hofman, Louise Emmett, John Violet et al. · British Journal of Urology · 2019 · 162 citations · Full text

Medicine, Oncology, Pharmacology +17

Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy

Arnoud J. Templeton, Jennifer J. Knox, Xun Lin et al. · European Urology · 2016 · 151 citations · Full text

Medicine, Immunology, Oncology +14

Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma

Nizar M. Tannir, Neeraj Agarwal, Camillo Porta et al. · JAMA Oncology · 2022 · 142 citations · Full text

Medicine, Oncology, Pharmacology +17